Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism
暂无分享,去创建一个
John C Lindon | Jeremy K Nicholson | J. Lindon | J. Nicholson | J. Everett | T. A. Clayton | D. Baker | T Andrew Clayton | David Baker | Jeremy R Everett | Dave J. Baker
[1] M. Mikov. The metabolism of drugs by the gut flora , 1994, European Journal of Drug Metabolism and Pharmacokinetics.
[2] Jeremy K. Nicholson,et al. Gut microbiota: a potential new territory for drug targeting , 2008, Nature Reviews Drug Discovery.
[3] Ge Zhang,et al. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. , 2008, Drug metabolism reviews.
[4] M. Ala-Korpela. Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool , 2007, Expert review of molecular diagnostics.
[5] I. Kato,et al. Fasting enhances p-Cresol production in the rat intestinal tract. , 2007, Experimental animals.
[6] Liping Zhao,et al. Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. , 2007, Journal of proteome research.
[7] Johan Trygg,et al. Chemometrics in metabonomics. , 2007, Journal of proteome research.
[8] R. Vanholder,et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] D. Bessesen,et al. Human gut microbes associated with obesity , 2007 .
[10] Jennifer L. Martin,et al. Human cytosolic sulfotransferase SULT1A1. , 2007, The international journal of biochemistry & cell biology.
[11] A. Daly,et al. Individualized drug therapy. , 2007, Current opinion in drug discovery & development.
[12] Douglas B. Kell,et al. Statistical strategies for avoiding false discoveries in metabolomics and related experiments , 2007, Metabolomics.
[13] P. Turnbaugh,et al. Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.
[14] D. Nebert,et al. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. , 2006, Trends in pharmacological sciences.
[15] H. McLeod,et al. Pharmacogenomics: from bedside to clinical practice. , 2006, Human molecular genetics.
[16] J. Lindon,et al. Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.
[17] Jennifer L. Martin,et al. Human sulfotransferases and their role in chemical metabolism. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[18] Michel Eichelbaum,et al. Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.
[19] Zhengyin Yan,et al. BIOACTIVATION OF 4-METHYLPHENOL (p-CRESOL) VIA CYTOCHROME P450-MEDIATED AROMATIC OXIDATION IN HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.
[20] M. Duffel,et al. FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF α-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS , 2005, Drug Metabolism and Disposition.
[21] T. Meyer,et al. Removal of P-cresol sulfate by hemodialysis. , 2005, Journal of the American Society of Nephrology : JASN.
[22] Anne L McCartney,et al. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. , 2005, Journal of medical microbiology.
[23] K. Verbeke,et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. , 2005, Clinical chemistry.
[24] I. Wilson,et al. Gut microorganisms, mammalian metabolism and personalized health care , 2005, Nature Reviews Microbiology.
[25] Gerardo Barragán-Mejía,et al. Effect of toluene and cresols on Na+,K+-ATPase, and serotonin in rat brain. , 2005, Regulatory toxicology and pharmacology : RTP.
[26] S. Finegold,et al. Real-Time PCR Quantitation of Clostridia in Feces of Autistic Children , 2004, Applied and Environmental Microbiology.
[27] M. Relling,et al. Moving towards individualized medicine with pharmacogenomics , 2004, Nature.
[28] C. Fuke,et al. Quantitative analysis of cresol and its metabolites in biological materials and distribution in rats after oral administration. , 2004, Legal medicine.
[29] F. Kauffman. Sulfonation in Pharmacology and Toxicology , 2004, Drug metabolism reviews.
[30] Elaine Holmes,et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis , 2004, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[31] M. Coughtrie,et al. Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1 , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[32] J. Blalock,et al. The requirement of ammonium or other cations linked with p-cresol sulfate for cross-reactivity with a peptide of myelin basic protein. , 2003, Archives of biochemistry and biophysics.
[33] I. Wilson,et al. Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.
[34] D. Nebert,et al. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. , 2003, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
[35] D. Tibboel,et al. Modelling paracetamol urine metabolites , 2002 .
[36] C. Strott. Sulfonation and molecular action. , 2002, Endocrine reviews.
[37] Ram H Datar,et al. Role of genetic and expression profiling in pharmacogenomics: the changing face of patient management. , 2002, Current issues in molecular biology.
[38] G. Macfarlane,et al. Variation in human intestinal microbiota with age. , 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[39] Karoly Horvath,et al. Autism and gastrointestinal symptoms , 2002, Current gastroenterology reports.
[40] M. Coughtrie. Sulfation through the looking glass—recent advances in sulfotransferase research for the curious , 2002, The Pharmacogenomics Journal.
[41] W. Bodell,et al. Formation of DNA adducts by microsomal and peroxidase activation of p-cresol: role of quinone methide in DNA adduct formation. , 2001, Chemico-biological interactions.
[42] M Heath-Chiozzi,et al. Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.
[43] J. Johnson,et al. Pharmacogenomics: the inherited basis for interindividual differences in drug response. , 2001, Annual review of genomics and human genetics.
[44] P. Burney,et al. Paracetamol sales and atopic disease in children and adults: an ecological analysis. , 2000, The European respiratory journal.
[45] E. Tanaka,et al. Update: the clinical importance of acetaminophen hepatotoxicity in non‐alcoholic and alcoholic subjects , 2000, Journal of clinical pharmacy and therapeutics.
[46] L. Coward,et al. p-Cresol sulfate is the dominant component of urinary myelin basic protein like material. , 2000, Archives of biochemistry and biophysics.
[47] R. Vanholder,et al. p-cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[48] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[49] Maurizio Elia,et al. Sulphation deficit in “low-functioning” autistic children: a pilot study , 1999, Biological Psychiatry.
[50] B. Burchell,et al. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. , 1997, Environmental health perspectives.
[51] C. Klaassen,et al. The importance of 3‘‐phosphoadenosine 5‘‐phosphosulfate (PAPS) in the regulation of sulfation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[52] G. Macfarlane,et al. Formation of Phenolic and Indolic Compounds by Anaerobic Bacteria in the Human Large Intestine , 1997, Microbial Ecology.
[53] J. Elliott,et al. Voltage-dependent inhibition of RCK1 K+ channels by phenol, p-cresol, and benzyl alcohol. , 1997, Molecular pharmacology.
[54] D. Thompson,et al. Quinone methide formation from para isomers of methylphenol (cresol), ethylphenol, and isopropylphenol: relationship to toxicity. , 1995, Chemical research in toxicology.
[55] G. D. Block,et al. Association of acetaminophen hepatotoxicity with fasting and ethanol use. , 1994, JAMA.
[56] J. Critchley,et al. The estimation of paracetamol and its major metabolites in both plasma and urine by a single high-performance liquid chromatography assay. , 1994, Journal of pharmaceutical and biomedical analysis.
[57] R. Fisher,et al. Cresol isomers: comparison of toxic potency in rat liver slices. , 1994, Toxicology and applied pharmacology.
[58] O. Hänninen,et al. Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. , 1992, The Journal of nutrition.
[59] P. Emery,et al. Metabolism of low-dose paracetamol in patients with rheumatoid arthritis. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.
[60] H. V. Sims,et al. Presumptive identification of Clostridium difficile by detection of p-cresol in prepared peptone yeast glucose broth supplemented with p-hydroxyphenylacetic acid , 1990, Journal of clinical microbiology.
[61] R. Waring,et al. Metabolism of low-dose paracetamol in patients with chronic neurological disease. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.
[62] B. Ramakrishna,et al. Estimation of phenolic conjugation by colonic mucosa. , 1989, Journal of clinical pathology.
[63] I. Rowland. Interactions of the Gut Microflora and the Host in Toxicology , 1988, Toxicologic pathology.
[64] P. Goodhart,et al. Mechanism-based inactivation of dopamine beta-hydroxylase by p-cresol and related alkylphenols. , 1987, Biochemistry.
[65] L F Prescott,et al. Inter-subject and ethnic differences in paracetamol metabolism. , 1986, British journal of clinical pharmacology.
[66] R. Galinsky,et al. Influence of advanced age on the formation and elimination of acetaminophen metabolites by male rats. , 1986, Pharmacology.
[67] I. Rowland. Reduction by the gut microflora of animals and man. , 1986, Biochemical pharmacology.
[68] R. F. Adams,et al. HIGH LEVELS OF FAECAL p-CRESOL IN A GROUP OF HYPERACTIVE CHILDREN , 1985, The Lancet.
[69] J. Mccall,et al. Sulfation of minoxidil by liver sulfotransferase. , 1982, Biochemical pharmacology.
[70] J. Clements,et al. Clinical Pharmacokinetics of Paracetamol , 1982, Clinical pharmacokinetics.
[71] I. Rowland. The influence of the gut microflora on food toxicity , 1981, Proceedings of the Nutrition Society.
[72] L F Prescott,et al. Kinetics and metabolism of paracetamol and phenacetin. , 1980, British journal of clinical pharmacology.
[73] L F Prescott,et al. Kinetics of acetaminophen absorption and gastric emptying in man , 1978, Clinical pharmacology and therapeutics.
[74] A. Tamm,et al. The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. , 1976, The American journal of clinical nutrition.
[75] A. Cummings,et al. A kinetic study of drug elimination: the excretion of paracetamol and its metabolites in man. , 1967, British journal of pharmacology and chemotherapy.
[76] R. Strang,et al. THE ASSOCIATION OF GASTRO‐DUODENAL ULCERATION AND PARKINSON'S DISEASE , 1965, The Medical journal of Australia.